Glaxo flu vaccine sales pegged at $2.1B

As the swine flu gathers pace around the world, analysts forecast windfall orders for GlaxoSmithKline's H1N1 vaccine, which they expect to generate at least $2.1 billion in sales next year. Report

Suggested Articles

At one point, Novartis even offered up $90 apiece for the inclisiran developer but would later say even $85 was too much, a securities filing shows.

Sanofi spent months hyping its Tuesday investor event, and new CEO Paul Hudson certainly laid out a different vision for the drugmaker at the confab.

After more than 10 years as partners, Sanofi and Regeneron are splitting up their deal to comarket PCSK9 med Praluent and immunology drug Kevzara.